[pubmed] Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases
Posté : 23 août 2021 12:00
Tumori. 2021 Aug 21:3008916211040559. doi: 10.1177/03008916211040559. Online ahead of print.
ABSTRACT
Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis observed at the Modena Cancer Center in two elderly patients treated with two anti-PD-1 monoclonal antibodies: cemiplimab and nivolumab.
PMID:34423700 | DOI:10.1177/03008916211040559
Source: https://pubmed.ncbi.nlm.nih.gov/3442370 ... 5&v=2.14.5